{
    "nctId": "NCT00331630",
    "briefTitle": "Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer",
    "officialTitle": "Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Clinical Response Rate (cRR)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed breast cancer\n\n  * Clinical stage I-III disease\n* Measurable disease defined as \u2265 1 unidimensionally measurable lesion \u2265 20 mm by conventional techniques OR \u2265 10 mm with spiral CT scan\n* HER2/neu 3+ by immunohistochemistry or positive by fluorescent in situ hybridization\n* No known brain metastases\n* Hormone receptor status unspecified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Male or female\n* Life expectancy \\> 12 weeks\n* ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100%\n* WBC \u2265 3,000/mm\\^3\n* Absolute neutrophil count \u2265 1,500 mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Total bilirubin normal\n* AST and ALT \u2264 2.5 times upper limit of normal\n* Creatinine normal OR creatinine clearance \u2265 60 mL/min\n* LVEF \u2265 50% as measured by echocardiogram or MUGA scan\n* No other malignancy within the past year\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Able to swallow and retain oral medication\n* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib\n* No ongoing or active infection\n* No symptomatic congestive heart failure\n* No unstable angina pectoris\n* No cardiac arrhythmia\n* No psychiatric illness or social situation that would preclude study compliance\n* No other uncontrolled illness\n* No gastrointestinal (GI) tract disease that would preclude ability to take oral medication\n* No malabsorption syndrome\n* No requirement for IV alimentation\n* No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior chemotherapy, immunotherapy, radiotherapy, or hormonal therapy for breast cancer\n* No prior treatment with epidermal growth factor receptor targeting therapies\n* No prior surgical procedures affecting absorption\n* No prior surgery for breast cancer\n* At least 14 days since prior and no concurrent CYP3A4 inducers, including any of the following:\n\n  * Dexamethasone or dexamethasone equivalent dose \u2265 1.5 mg/day, including any of the following:\n\n    * Cortisone (\u2265 50 mg/day)\n    * Hydrocortisone (\u2265 40 mg/day)\n    * Prednisone (\u2265 10 mg/day)\n    * Methylprednisolone (\u2265 8 mg/day)\n  * Phenytoin\n  * Carbamazepine\n  * Phenobarbital\n  * Efavirenz\n  * Nevirapine\n  * Rifampin\n  * Rifabutin\n  * Rifapentine\n  * Hypericum perforatum (St. John's wort)\n  * Modafinil\n* At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following:\n\n  * Clarithromycin\n  * Erythromycin\n  * Troleandomycin\n  * Delavirdine\n  * Ritonavir\n  * Indinavir\n  * Saquinavir\n  * Nelfinavir\n  * Amprenavir\n  * Lopinavir\n  * Itraconazole\n  * Ketoconazole\n  * Voriconazole\n  * Fluconazole (doses up to 150 mg/day are permitted)\n  * Nefazodone\n  * Fluvoxamine\n  * Verapamil\n  * Diltiazem\n  * Cimetidine\n  * Aprepitant\n  * Grapefruit or its juice\n* At least 6 months since prior and no concurrent amiodarone\n* At least 2 days since prior and no concurrent gastric pH modifiers\\*, including any of the following:\n\n  * Cimetidine\n  * Ranitidine\n  * Nizatidine\n  * Famotidine\n  * Omeprazole\n  * Esomeprazole\n  * Rabeprazole\n  * Pantoprazole\n  * Lansoprazole\n* NOTE: \\*Antacids are allowed within 1 hour before and after administration of study drug\n* No other concurrent investigational agents\n* No other concurrent anticancer therapy, including chemotherapy, radiotherapy, immunotherapy, or antitumor hormonal therapy\n* No concurrent herbal (alternative) medicines\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* Concurrent bisphosphonates allowed",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}